Literature DB >> 7442733

Effects of cysteamine therapy in nephropathic cystinosis.

M Yudkoff, J W Foreman, S Segal.   

Abstract

We studied the effects of cysteamine in five children with nephropathic cystinosis who were treated for up to 30 months. Cysteamine caused a decline in leukocyte cystine levels to the range seen in clinically unaffected heterozygotes; both plasma and urinary cystine diminished by more than half. Therapy had no effect on progressively declining creatinine clearance in three patients, but improvement occurred in the other two. Phosphaturia, glycosuria, aminociduria, and organic aciduria did not improve in any of the patients. Both blood lactate and the lactate pyruvate ratio were diminished. Growth velocity, which was abnormal in four of the five children, did not improve. No major side effects were noted. Therapy with cysteamine caused a consistent, dose-related decline in levels of cystine in leukocytes and in extracellular fluid, caused no improvement so far in renal tubular function or growth velocity, and improved creatinine clearance in some patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7442733     DOI: 10.1056/NEJM198101153040303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  10 in total

1.  Infantile nephropathic cystinosis presenting as incomplete Fanconi syndrome and refractory rickets.

Authors:  V S Rajadurai; P Shanbag; M S Seshadri; U Khanduri; T A Alexander; M A Jadhav
Journal:  Indian J Pediatr       Date:  1989 May-Jun       Impact factor: 1.967

2.  Predicted reciprocal serum creatinine at age 10 years as a measure of renal function in children with nephropathic cystinosis treated with oral cysteamine.

Authors:  W A Gahl; J A Schneider; J D Schulman; J G Thoene; G F Reed
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

3.  Dissecting aneurysm of aorta in rats fed with cysteamine.

Authors:  A P Jayaraj
Journal:  Br J Exp Pathol       Date:  1983-10

4.  The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire.

Authors:  W G van't Hoff; N Gretz
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

5.  Metabolism of pantethine in cystinosis.

Authors:  C T Wittwer; W A Gahl; J D Butler; M Zatz; J G Thoene
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

6.  Renal cell culture using autopsy material from children with cystinosis.

Authors:  O L Pellett; M L Smith; J G Thoene; J A Schneider; A J Jonas
Journal:  In Vitro       Date:  1984-01

7.  Enhancement of residual arylsulfatase B activity in feline mucopolysaccharidosis VI by thiol-induced subunit association.

Authors:  D T Vine; M M McGovern; E H Schuchman; M E Haskins; R J Desnick
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

8.  Progression of chronic renal failure in a historical group of patients with nephropathic cystinosis. European Collaborative Study on Cystinosis.

Authors:  F Manz; N Gretz
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

9.  Reduction of the secretory response to Escherichia coli heat-stable enterotoxin by thiol and disulfide compounds.

Authors:  R N Greenberg; J A Dunn; R L Guerrant
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

10.  Effect of indomethacin on clinical progress and renal function in cystinosis.

Authors:  G B Haycock; J Al-Dahhan; R H Mak; C Chantler
Journal:  Arch Dis Child       Date:  1982-12       Impact factor: 3.791

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.